

Inhalation Sciences



PRESS RELEASE
Published: 15-12-2022

DDL2022: Inhalation Sciences had several landmark presentations at well-attended event

At this year's DDL in Edinburgh, Scotland (7-9 December) Inhalation Sciences AB (ISAB) presented, for the first time, data from its clinical study of Preciselnhale, showing how the system out-performed commercial inhalers in targeting aerosols to specified regions of the lung. A second poster on ISAB's *in vitro* simulation module DissolvIt was also presented. This was the first onsite DDL event since the end of European Covid-19 restrictions.

DDL conferences (Drug Delivery to the Lungs) are some of the most well-attended events in the global inhalation industry's calendar. As the first DDL onsite following Covid19, DDL 2022 was particularly busy, with visitors from across the industry. ISAB was represented at the event by CEO Manoush Masarrat and CSO and Founder Assoc Prof Per Gerde at Booth 346.

CEO Manoush Masarrat: "We had a lot of traffic at the stand. Interest and awareness of both our technology and research services was really high. We met a broad mix of potential customers, from generics and biologics to NCE (New Chemical Entities.) It was a very productive conference – we started many fruitful dialogues that we now definitely intend to comminute."

First clinical findings on Preciselnhale presented

For the first time ISAB publicly presented results from its landmark clinical study of Preciselnhale in Poster 55. The poster, titled 'Using Preciselnhale for Controlled Volunteer Exposures with Aerosols Extracted from Clinical Inhalers', was authored by P.Gerde et al. The findings demonstrate how aerosol exposures of healthy volunteers with Preciselnhale would result in much higher plasma levels of a drug in comparison with exposures administered with a pMDI using the same substance.

Additionally, data from the poster demonstrate how Preciselnhale out-performed commercial inhalers in targeting aerosols to specified regions of the respiratory tract including the deep lung.

Poster co-authored by Hovione presented

In the second Poster 53 ('Simulation lung dissolution - fast tracking DPI development' by Hovione's B. Noriega-Fernandes et al.) ISAB shared findings demonstrating how DissolvIt can discriminate across several testing micronization methods, formulations and APIs.

Main stage presentation by AstraZeneca

In a main stage podium Dr. Rebecca Fransson (Associate Director in Advanced Drug Delivery, Pharmaceutical Sciences at AstraZeneca in Gothenburg, Sweden) delivered the presentation 'Translation of inhaled exposure throughout drug development: A case-study on

how to de-risk formulation development and secure clinical exposure.' The presentation described how PreciseInhale was successfully used in an *in vivo* study administering aerosol exposures to larger lungs, that have a higher correlation to human data.

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.